Journal articleJ Pain Symptom Manage · April 2026
CONTEXT: Caring for individuals with serious illness and opioid or stimulant use disorder (OUD/STuD) is complex. Palliative care (PC) providers often lack addiction medicine training and report discomfort managing this population. OBJECTIVES: This quality ...
Full textLink to itemCite
Journal articleJ Addict Med · March 2026
OBJECTIVES: Peripartum opioid use disorder (OUD) is a significant public health concern. Although hospital admission for labor and delivery is common, little is known about hospitalized peripartum individuals with OUD or their inpatient management. The pur ...
Full textLink to itemCite
Journal articleJ Gen Intern Med · January 2026
BACKGROUND: Medication for opioid use disorder (MOUD) reduces mortality and is the standard of care yet use remains low. Hospitalist-led treatment can fill important gaps in care for patients with OUD. OBJECTIVE: Evaluate effectiveness of a hospitalist-led ...
Full textLink to itemCite
Journal articleJ Hosp Med · January 2025
BACKGROUND: Stigma within the healthcare environment limits access to treatment for opioid use disorder (OUD), even as OUD results in significant morbidity and mortality. Language in clinical documentation affects patient experience and future care through ...
Full textLink to itemCite
Journal articleLancet Microbe · June 1, 2024
Background: Serial measurement of virological and immunological biomarkers in patients admitted to hospital with COVID-19 can give valuable insight into the pathogenic roles of viral replication and immune dysregulation. We aimed to characterise biomarker ...
Full textCite
Journal articleLancet Respir Med · October 2022
BACKGROUND: Tixagevimab-cilgavimab is a neutralising monoclonal antibody combination hypothesised to improve outcomes for patients hospitalised with COVID-19. We aimed to compare tixagevimab-cilgavimab versus placebo, in patients receiving remdesivir and o ...
Full textOpen AccessLink to itemCite
Journal articleAnn Intern Med · September 2022
BACKGROUND: Ensovibep (MP0420) is a designed ankyrin repeat protein, a novel class of engineered proteins, under investigation as a treatment of SARS-CoV-2 infection. OBJECTIVE: To investigate if ensovibep, in addition to remdesivir and other standard care ...
Full textOpen AccessLink to itemCite
Journal articleJ Hosp Med · June 2022
BACKGROUND: As opioid-related hospitalizations rise, hospitals must be prepared to evaluate and treat patients with opioid use disorder (OUD). We implemented a hospitalist-led program, Project Caring for patients with Opioid Misuse through Evidence-based T ...
Full textLink to itemCite
Journal articleJ Opioid Manag · 2021
The coronavirus disease 2019 (COVID-19) pandemic has had harmful effects on the opioid epidemic. While a negative effect was predicted, we report on this reality in the hospital setting. We have seen a sharp rise in hospitalized patients with opioid use di ...
Full textLink to itemCite